Can-Fite BioPharma (NYSE:CANF – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Can-Fite BioPharma and CorMedix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Can-Fite BioPharma | 0 | 1 | 2 | 0 | 2.67 |
| CorMedix | 0 | 2 | 8 | 0 | 2.80 |
Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 2,966.20%. CorMedix has a consensus target price of $15.22, indicating a potential upside of 188.85%. Given Can-Fite BioPharma’s higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than CorMedix.
Risk and Volatility
Valuation and Earnings
This table compares Can-Fite BioPharma and CorMedix”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Can-Fite BioPharma | $405,000.00 | 5.37 | -$7.63 million | ($14.80) | -0.10 |
| CorMedix | $311.71 million | 1.34 | $163.05 million | $0.69 | 7.64 |
CorMedix has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Can-Fite BioPharma and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Can-Fite BioPharma | N/A | N/A | N/A |
| CorMedix | 15.49% | 26.70% | 13.61% |
Summary
CorMedix beats Can-Fite BioPharma on 12 of the 14 factors compared between the two stocks.
About Can-Fite BioPharma
Can-Fite BioPharma is an Israeli clinical-stage biopharmaceutical company founded in 2000. It develops small-molecule drugs that target adenosine receptors, with the goal of treating inflammatory, cancerous and other diseases. The company’s pipeline includes piclidenoson, which it is developing for conditions including psoriasis and rheumatoid arthritis, and namodenoson, which it is studying for liver cancer and other indications. Can-Fite has also developed CF602 for potential use in erectile dysfunction.
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
